Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.

To claim your copy free of charge simply follow this link.

Matthew Fust Biography and Net Worth

Director of Crinetics Pharmaceuticals

Mr. Fust joined Ultragenyx as a board member in January 2014. He is a board member and advisor to life sciences companies. Mr. Fust retired as Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc. from January 2009 until January 2014. From May 2003 to December 2008, Mr. Fust served as Chief Financial Officer of Jazz Pharmaceuticals, Inc. From 2002 to 2003, Mr. Fust served as Chief Financial Officer at Perlegen Sciences. Previously, he was Senior Vice President and Chief Financial Officer at ALZA Corporation, where he was an executive from 1996 until 2002. From 1991 until 1996, Mr. Fust was a manager in the healthcare strategy practice at Andersen Consulting. Mr. Fust serves on the board of directors of Atara Biotherapeutics, Inc., and Crinetics Pharmaceuticals, Inc. Mr. Fust received his B.A. from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business.

What is Matthew K. Fust's net worth?: The estimated net worth of Matthew K. Fust is at least $1.13 million as of October 18th, 2024. Mr. Fust owns 20,100 shares of Crinetics Pharmaceuticals stock worth more than $1,127,007 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Fust may own. Learn More about Matthew K. Fust's net worth.
How do I contact Matthew K. Fust?: The corporate mailing address for Mr. Fust and other Crinetics Pharmaceuticals executives is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. Crinetics Pharmaceuticals can also be reached via phone at (858) 450-6464 and via email at [email protected]. Learn More on Matthew K. Fust's contact information.
Has Matthew K. Fust been buying or selling shares of Crinetics Pharmaceuticals?: Matthew K. Fust has not been actively trading shares of Crinetics Pharmaceuticals in the last ninety days. Most recently, Matthew K. Fust sold 60,000 shares of the business's stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $44.14, for a transaction totalling $2,648,400.00. Following the completion of the sale, the director now directly owns 18,536 shares of the company's stock, valued at $818,179.04. Learn More on Matthew K. Fust's trading history.
Who are Crinetics Pharmaceuticals' active insiders?: Crinetics Pharmaceuticals' insider roster includes Stephen Betz (Insider), Matthew Fust (Director), James Hassard (Chief Commercial Officer), Jeff Knight (COO), Alan Krasner (Chief Endocrinologist), Ajay Madan (Insider), Stephanie Okey (Director), Dana Pizzuti (Chief Medical and Development Officer), Richard Struthers (CEO), and Marc Wilson (CFO). Learn More on Crinetics Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Crinetics Pharmaceuticals?: During the last year, insiders at the sold shares 34 times. They sold a total of 560,048 shares worth more than $26,278,027.53. The most recent insider tranaction occured on October, 3rd when insider Dana Pizzuti sold 14,375 shares worth more than $785,306.25. Insiders at Crinetics Pharmaceuticals own 6.0% of the company. Learn More about insider trades at Crinetics Pharmaceuticals.
Information on this page was last updated on 10/3/2024.

Matthew K. Fust Insider Trading History at Crinetics Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/20/2024	Sell	60,000	$44.14	$2,648,400.00	18,536
7/13/2022	Sell	5,700	$20.96	$119,472.00	12,536
11/1/2021	Sell	8,954	$25.50	$228,327.00
9/8/2021	Sell	6,046	$25.50	$154,173.00	18,582
7/26/2021	Sell	5,000	$19.59	$97,950.00
7/19/2021	Sell	5,000	$19.50	$97,500.00	17,536
7/12/2021	Sell	5,000	$20.71	$103,550.00
12/16/2019	Sell	3,500	$22.50	$78,750.00	16,036

Matthew K. Fust Buying and Selling Activity at Crinetics Pharmaceuticals

Crinetics Pharmaceuticals Company Overview

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Today's Range

Now: $56.07

$54.64

$56.43

50 Day Range

MA: $55.20

$49.82

$60.69

2 Week Range

Now: $56.07

$29.72

$62.53

Volume

493,583 shs

Average Volume

627,079 shs

Market Capitalization

$5.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

Download Our Tesla Ebook For Free

From DTI | Ad